Cymabay Therapeutics Inc expected to post a loss of 26  cents a share - Earnings Preview

CymaBay Therapeutics

15/03/2022 11:07

* Cymabay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show
a rise in quarterly revenue when it reports  results on March
17. 
    * The Newark California California-based  company is
expected to
report revenue of $6.429 million, according to the mean estimate
from 7 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Cymabay
Therapeutics Inc
is for a loss of 26 cents per share. For the same quarter last
year, the company reported a loss of 23 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $11.5​, above​ its last closing price
of $2.97. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.28       -0.26      -0.33     Missed  -25.4
 Jun. 30 2021  -0.27       -0.27      -0.34     Missed  -27
 Mar. 31 2021  -0.25       -0.24      -0.25     Missed  -2.4​
 Dec. 31 2020              -0.20      -0.23     Missed  -14.9
 ​​Sep.        -0.17       -0.17      -0.17     Met     -2.4
 30 2020                                                
 Jun. 30 2020  -0.23       -0.24      -0.16     Beat    33.1​
 Mar. 31 2020  -0.30       -0.30      -0.19     Beat    36.5
 Dec. 31 2019  -0.37       -0.39      -0.35     Beat    10
 This summary was machine generated March 15 at 11:07 GMT.  All
figures in US dollars  unless otherwise stated